Human Immunodeficiency Virus 1 (HIV-1) PhenoSense GT® (Monogram® Phenotype/Genotype)
CPT:
87900; 87901; 87903; 87904(x12)
Synonyms
- HIV-1 Resistance
- PhenoSense GT®
Special Instructions
A separate frozen specimen is required for each frozen test ordered. This assay is a combined assay in which HIV genotype and HIV phenotype is performed.
Expected Turnaround Time
16 - 22 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
For more information, please view the literature below.
Specimen Requirements
Specimen
Plasma, frozen
Volume
3 mL
Container
Lavender-top (EDTA) or plasma preparation tube (PPT™)
Collection
Collect specimen in two lavender-top (EDTA) tubes or two PPT™ tubes. Do not use green-top (heparin) tubes. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) (not "pop-top" or "snap-cap"), and freeze. Ship specimen frozen. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Freeze
Causes for Rejection
PPT™ not centrifuged; quantity not sufficient for analysis; heparinized plasma; nonfrozen specimen; specimen exposed to repeated freeze/thaw cycles; specimen received in “pop-top” or “snap-cap” tube
Test Details
Use
Determines viral phenotype and genotype resistance to three classes of commonly prescribed antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI). Viral replication capacity is also included.
Limitations
This procedure should be used for patients with documented HIV-1 infection and viral loads ≥500 copies/mL.
Methodology
Phenotype: polymerase chain reaction (PCR) amplification and viral culture; genotype: polymerase chain reaction (PCR) and DNA sequencing. PhenoSense® and PhenoSense GT® are trademarks of Monogram Biosciences®.
References
Baxter JD, Mayers DL, Wentworth DN, et al. CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999. Abstract LB8.
Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999; 282(12):1135-1141. 10501116
Cohen C, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy (Tx): A randomized trial (VIRA3001). Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif: 2000. Abstract 237.
Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet. 1999; 353(9171):2195-2199. Erratum: Lancet. 1999; 354(9184):1128. 10392984
Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999; 282(12):1142-1149. 10501117
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Washington, DC: Department of Health and Human Services. January 28, 2000. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 10, 2012.
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 551690 | PhenoSense GT (R) | 551601 | PhenoSense GT(R) PDF | 51969-4 | ||
| 551690 | PhenoSense GT (R) | 551602 | PhenoSense(R) PDF | 51969-4 | ||
| 551690 | PhenoSense GT (R) | 551603 | GeneSeq(R) PDF | 51969-4 | ||
| 551690 | PhenoSense GT (R) | 551604 | PSGT-Net Assessment | 19146-0 | ||
| 551690 | PhenoSense GT (R) | 551605 | PSGT-PhenoSense(R) Results | 49665-3 | ||
| 551690 | PhenoSense GT (R) | 551608 | PSGT-GeneSeq(R) Results | 53798-5 | ||
| 551690 | PhenoSense GT (R) | 551609 | PSGT-Net Assessment Interp. | 77202-0 | ||
| 551690 | PhenoSense GT (R) | 551617 | PSGT-PhenoSense(R) Interp. | 62364-5 | ||
| 551690 | PhenoSense GT (R) | 551618 | PSGT-GeneSeq(R) Interp. | 62364-5 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf